342 related articles for article (PubMed ID: 23459190)
41. Tumor microenvironmental conversion of natural killer cells into myeloid-derived suppressor cells.
Park YJ; Song B; Kim YS; Kim EK; Lee JM; Lee GE; Kim JO; Kim YJ; Chang WS; Kang CY
Cancer Res; 2013 Sep; 73(18):5669-81. PubMed ID: 23867469
[TBL] [Abstract][Full Text] [Related]
42. G-CSF stem cell mobilization in human donors induces polymorphonuclear and mononuclear myeloid-derived suppressor cells.
Luyckx A; Schouppe E; Rutgeerts O; Lenaerts C; Fevery S; Devos T; Dierickx D; Waer M; Van Ginderachter JA; Billiau AD
Clin Immunol; 2012 Apr; 143(1):83-7. PubMed ID: 22341087
[TBL] [Abstract][Full Text] [Related]
43. Neutrophils: Critical components in experimental animal models of cancer.
Hagerling C; Werb Z
Semin Immunol; 2016 Apr; 28(2):197-204. PubMed ID: 26976824
[TBL] [Abstract][Full Text] [Related]
44. Serum inhibits the immunosuppressive function of myeloid-derived suppressor cells isolated from 4T1 tumor-bearing mice.
Hamilton MJ; Banáth JP; Lam V; Lepard NE; Krystal G; Bennewith KL
Cancer Immunol Immunother; 2012 May; 61(5):643-54. PubMed ID: 22021068
[TBL] [Abstract][Full Text] [Related]
45. IL-35 induces N2 phenotype of neutrophils to promote tumor growth.
Zou JM; Qin J; Li YC; Wang Y; Li D; Shu Y; Luo C; Wang SS; Chi G; Guo F; Zhang GM; Feng ZH
Oncotarget; 2017 May; 8(20):33501-33514. PubMed ID: 28432279
[TBL] [Abstract][Full Text] [Related]
46. Mast cell-deficient Kit(W-sh) "Sash" mutant mice display aberrant myelopoiesis leading to the accumulation of splenocytes that act as myeloid-derived suppressor cells.
Michel A; Schüler A; Friedrich P; Döner F; Bopp T; Radsak M; Hoffmann M; Relle M; Distler U; Kuharev J; Tenzer S; Feyerabend TB; Rodewald HR; Schild H; Schmitt E; Becker M; Stassen M
J Immunol; 2013 Jun; 190(11):5534-44. PubMed ID: 23636054
[TBL] [Abstract][Full Text] [Related]
47. Role of the Neutrophil in the Pathogenesis of Advanced Cancer and Impaired Responsiveness to Therapy.
Rapoport BL; Steel HC; Theron AJ; Smit T; Anderson R
Molecules; 2020 Apr; 25(7):. PubMed ID: 32244751
[TBL] [Abstract][Full Text] [Related]
48. Myeloid-derived suppressor cells: Important contributors to tumor progression and metastasis.
Safarzadeh E; Orangi M; Mohammadi H; Babaie F; Baradaran B
J Cell Physiol; 2018 Apr; 233(4):3024-3036. PubMed ID: 28661031
[TBL] [Abstract][Full Text] [Related]
49. Cyclophosphamide-induced myeloid-derived suppressor cell population is immunosuppressive but not identical to myeloid-derived suppressor cells induced by growing TC-1 tumors.
Mikyšková R; Indrová M; Polláková V; Bieblová J; Símová J; Reiniš M
J Immunother; 2012 Jun; 35(5):374-84. PubMed ID: 22576342
[TBL] [Abstract][Full Text] [Related]
50. Transcriptomic analysis comparing tumor-associated neutrophils with granulocytic myeloid-derived suppressor cells and normal neutrophils.
Fridlender ZG; Sun J; Mishalian I; Singhal S; Cheng G; Kapoor V; Horng W; Fridlender G; Bayuh R; Worthen GS; Albelda SM
PLoS One; 2012; 7(2):e31524. PubMed ID: 22348096
[TBL] [Abstract][Full Text] [Related]
51. Hierarchy of immunosuppressive strength among myeloid-derived suppressor cell subsets is determined by GM-CSF.
Dolcetti L; Peranzoni E; Ugel S; Marigo I; Fernandez Gomez A; Mesa C; Geilich M; Winkels G; Traggiai E; Casati A; Grassi F; Bronte V
Eur J Immunol; 2010 Jan; 40(1):22-35. PubMed ID: 19941314
[TBL] [Abstract][Full Text] [Related]
52. Phenotype, function and clinical implications of myeloid-derived suppressor cells in cancer patients.
Filipazzi P; Huber V; Rivoltini L
Cancer Immunol Immunother; 2012 Feb; 61(2):255-263. PubMed ID: 22120756
[TBL] [Abstract][Full Text] [Related]
53. Myeloid-Derived Suppressor Cells and Proinflammatory Cytokines as Targets for Cancer Therapy.
Atretkhany KN; Drutskaya MS
Biochemistry (Mosc); 2016 Nov; 81(11):1274-1283. PubMed ID: 27914453
[TBL] [Abstract][Full Text] [Related]
54. Unique pattern of neutrophil migration and function during tumor progression.
Patel S; Fu S; Mastio J; Dominguez GA; Purohit A; Kossenkov A; Lin C; Alicea-Torres K; Sehgal M; Nefedova Y; Zhou J; Languino LR; Clendenin C; Vonderheide RH; Mulligan C; Nam B; Hockstein N; Masters G; Guarino M; Schug ZT; Altieri DC; Gabrilovich DI
Nat Immunol; 2018 Nov; 19(11):1236-1247. PubMed ID: 30323345
[TBL] [Abstract][Full Text] [Related]
55. Fas signal promotes lung cancer growth by recruiting myeloid-derived suppressor cells via cancer cell-derived PGE2.
Zhang Y; Liu Q; Zhang M; Yu Y; Liu X; Cao X
J Immunol; 2009 Mar; 182(6):3801-8. PubMed ID: 19265159
[TBL] [Abstract][Full Text] [Related]
56. Tumor-derived lactate modifies antitumor immune response: effect on myeloid-derived suppressor cells and NK cells.
Husain Z; Huang Y; Seth P; Sukhatme VP
J Immunol; 2013 Aug; 191(3):1486-95. PubMed ID: 23817426
[TBL] [Abstract][Full Text] [Related]
57. Myeloid-derived suppressor cells in the tumor microenvironment: expect the unexpected.
Marvel D; Gabrilovich DI
J Clin Invest; 2015 Sep; 125(9):3356-64. PubMed ID: 26168215
[TBL] [Abstract][Full Text] [Related]
58. Role of myeloid regulatory cells (MRCs) in maintaining tissue homeostasis and promoting tolerance in autoimmunity, inflammatory disease and transplantation.
Amodio G; Cichy J; Conde P; Matteoli G; Moreau A; Ochando J; Oral BH; Pekarova M; Ryan EJ; Roth J; Sohrabi Y; Cuturi MC; Gregori S
Cancer Immunol Immunother; 2019 Apr; 68(4):661-672. PubMed ID: 30357490
[TBL] [Abstract][Full Text] [Related]
59. Tumor-Associated Macrophages and Neutrophils in Tumor Microenvironment.
Kim J; Bae JS
Mediators Inflamm; 2016; 2016():6058147. PubMed ID: 26966341
[TBL] [Abstract][Full Text] [Related]
60. Myeloid-Derived Suppressor Cells.
Gabrilovich DI
Cancer Immunol Res; 2017 Jan; 5(1):3-8. PubMed ID: 28052991
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
